INJE PharmacoGenomics Research Center

· Park MW, Her SH, Kim HS, Choi YS, Park CS, Koh YS, Park HJ, Kim PJ, Kim CJ, Jeon DS, Shin DI, Seo SM, Yoo KD, Kim DB, Kim HY, Lee JM, Chung WS, Seung KB, Shin JG, Chang K.

Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. (PRCDM)

Pharmacogenet Genomics. 23(10):558-62 / 2013.10 [LINK]

2013-International

· Kim KP, Kim HS, Sym SJ, Bae KS, Hong YS, Chang HM, Lee JL, Kang YK, Lee JS, Shin JG, Kim TW.

A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. (PRCDM)

Cancer Chemother Pharmacol. 71(6):1609-17 / 2013.06 [LINK]

2013-International

· Kim KM, Kim HS, Lim SH, Cheong SH, Choi EJ, Kang H, Choi HR, Jeon JW, Yon JH, Oh M, Shin JG.

Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. (PRCDM)

Int J Clin Pharmacol Ther. 51(5):383-92 / 2013.05 [LINK]

2013-International

· Shinde DD, Kim HS, Choi JS, Pan W, Bae SK, Yeo CW, Shon JH, Kim DH, Shin JG.

Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. (BMRC, PRCDM)

J Clin Pharmacol. 53(5):550-8 / 2013.05 [LINK]

2013-International

· Jiang F, Yeo CW, Lee SS, Oh MK, Ghim JL, Shon JH, Kim HS, Kim EY, Kim DH, Shin JG.

Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. (BMRC)

Pharmacogenet Genomics. 23(3):175-9 / 2013.03 [LINK]

2013-International

· Jiang F, Desta Z, Shon JH, Yeo CW, Kim HS, Liu KH, Bae SK, Lee SS, Flockhart DA, Shin JG.

Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. (PRCDM)

Br J Clin Pharmacol. 75(1):244-53 / 2013.01 [LINK]

2013-International

· Shinde DD, Kim KB, Oh KS, Abdalla N, Liu KH, Bae SK, Shon JH, Kim HS, Kim DH, Shin JG.

LC-MS/MS for the simultaneous analysis of arachidonic acid and 32 related metabolites in human plasma: Basal plasma concentrations and aspirin-induced changes of eicosanoids. (BMRC, PRCDM)

J Chromatogr B Analyt Technol Biomed Life Sci. 911:113-21 / 2012.12 [LINK]

2012-International

· Jo JC, Lee JL, Ryu MH, Chang HM, Kim M, Lee HJ, Kim HS, Shin JG, Kim TW, Kang YK

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. (PRCDM)

Br J Cancer. 106(10):1591-7 / 2012.05 [LINK]

2012-International

· Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, G

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. (BMRC)

Thromb Haemost. 107(2):232-40 / 2012.02 [LINK]

2012-International

· Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW.

Phase II study of S-1 and oxaliplatin for patients with metastatic biliary tract cancer: influence of CYP2A6 polymorphism on pharmacokinetics and clinical activity. (PRCDM)

Br J Cancer. 104(4):605-12 / 2011.02 [LINK]

2011-International

Publications

Product